生产企业：GSK
GSK-4532990 is being advanced under an exclusive licensing agreement with Arrowhead Pharmaceuticals and is currently in Phase II clinical evaluation for alcohol-associated liver disease (ALD). In November 2025, GSK presented results from its advancing liver pipeline, including GSK4532990, at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025.
GSK-4532990 is being advanced under an exclusive licensing agreement with Arrowhead Pharmaceuticals and is currently in Phase II clinical evaluation for alcohol-associated liver disease (ALD). In November 2025, GSK presented results from its advancing liver pipeline, including GSK4532990, at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025.
GSK-4532990 is an investigational RNA interference (RNAi) therapy that targets HSD17B13, a gene associated with susceptibility to liver disease. By suppressing hepatic HSD17B13 expression, the therapy seeks to mimic the protective effects observed in individuals carrying loss-of-function variants, thereby helping reduce liver inflammation and injury in diseases such as alcoholic hepatitis.
Alcohol-associated liver disease (ALD), including alcoholic hepatitis. Currently in Phase II clinical evaluation.
共 2 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
